Literature DB >> 9462199

Effects of cisapride on QTc interval in neonates.

S Bernardini1, D S Semama, F Huet, C Sgro, J B Gouyon.   

Abstract

AIM: Prospective survey of the effects of cisapride on QTc interval in neonates given cisapride.
METHODS: QTc interval was determined just before and 2.9 (0.9) days after outset of the treatment in 49 neonates treated with cisapride between 1 August 1995 and 29 February 1996.
RESULTS: Cisapride significantly increased QTc interval (p = 0.0001), and this was higher when birthweight or gestational age were lower. The prolongation of QTc interval above the arbitrary value of 0.450 (n = 7) was clinically asymptomatic and was significantly more common in the infants born with a gestational age < or = 33 weeks (n = 6).
CONCLUSION: The findings indicate that cisapride accumulates in less mature neonates. Further pharmacokinetic studies are needed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9462199      PMCID: PMC1720707          DOI: 10.1136/fn.77.3.f241

Source DB:  PubMed          Journal:  Arch Dis Child Fetal Neonatal Ed        ISSN: 1359-2998            Impact factor:   5.747


  15 in total

1.  Tachycardia during cisapride treatment.

Authors:  S Olsson; I R Edwards
Journal:  BMJ       Date:  1992-09-26

2.  Long-term use of cisapride (prepulsid) in premature neonates of less than 34 weeks gestational age.

Authors:  G Janssens; K Melis; M Vaerenberg
Journal:  J Pediatr Gastroenterol Nutr       Date:  1990-10       Impact factor: 2.839

3.  Long-term use of cisapride (Prepulsid) in premature neonates.

Authors:  K Melis; G Janssens
Journal:  Acta Gastroenterol Belg       Date:  1990 Jul-Aug       Impact factor: 1.316

Review 4.  Electrophysiologic mechanisms of the long QT interval syndromes and torsade de pointes.

Authors:  H L Tan; C J Hou; M R Lauer; R J Sung
Journal:  Ann Intern Med       Date:  1995-05-01       Impact factor: 25.391

5.  Interaction of triazolam and ketoconazole.

Authors:  D J Greenblatt; L L von Moltke; J S Harmatz; L M Harrel; S Tobias; R I Shader; C E Wright
Journal:  Lancet       Date:  1995-01-21       Impact factor: 79.321

6.  Long QT syndrome during high-dose cisapride.

Authors:  S Bran; W A Murray; I B Hirsch; J P Palmer
Journal:  Arch Intern Med       Date:  1995-04-10

7.  The role of cytochrome P450 in developmental pharmacology.

Authors:  A S Rogers
Journal:  J Adolesc Health       Date:  1994-12       Impact factor: 5.012

8.  The QT interval throughout the first 6 months of life: a prospective study.

Authors:  P J Schwartz; M Montemerlo; M Facchini; P Salice; D Rosti; G Poggio; R Giorgetti
Journal:  Circulation       Date:  1982-09       Impact factor: 29.690

Review 9.  QT-interval prolonging drugs: mechanisms and clinical relevance of their arrhythmogenic hazards.

Authors:  M Zehender; S Hohnloser; H Just
Journal:  Cardiovasc Drugs Ther       Date:  1991-04       Impact factor: 3.727

Review 10.  Cisapride. An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders.

Authors:  L R Wiseman; D Faulds
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

View more
  11 in total

1.  Varicella: to vaccinate or not to vaccinate?

Authors:  A Gershon
Journal:  Arch Dis Child       Date:  1998-12       Impact factor: 3.791

2.  How accurately can QT interval be measured in newborn infants?

Authors:  Katya De Groote; Bert Suys; An Deleeck; Daniël De Wolf; Dirk Matthys; Bart Van Overmeire
Journal:  Eur J Pediatr       Date:  2003-10-10       Impact factor: 3.183

Review 3.  Cytochrome P450 3A: ontogeny and drug disposition.

Authors:  S N de Wildt; G L Kearns; J S Leeder; J N van den Anker
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

4.  The risks and benefits of cisapride in premature neonates, infants, and children.

Authors:  A Lander; A Desai
Journal:  Arch Dis Child       Date:  1998-12       Impact factor: 3.791

5.  Application of the bradford hill criteria to assess the causality of cisapride-induced arrhythmia: a model for assessing causal association in pharmacovigilance.

Authors:  Michael Perrio; Simon Voss; Saad A W Shakir
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 6.  Efficacy and tolerability of cisapride in children.

Authors:  Y Vandenplas; A Benatar; F Cools; A Arana; B Hegar; B Hauser
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 7.  Drug interactions with cisapride: clinical implications.

Authors:  E L Michalets; C R Williams
Journal:  Clin Pharmacokinet       Date:  2000-07       Impact factor: 6.447

8.  Prone and left lateral positioning reduce gastro-oesophageal reflux in preterm infants.

Authors:  A K Ewer; M E James; J M Tobin
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1999-11       Impact factor: 5.747

9.  Evidence of impaired cisapride metabolism in neonates.

Authors:  J M Tréluyer; E Rey; M Sonnier; G Pons; T Cresteil
Journal:  Br J Clin Pharmacol       Date:  2001-10       Impact factor: 4.335

10.  Effects of cisapride on QTc interval in term neonates.

Authors:  D S Semama; S Bernardini; S Louf; B Laurent-Atthalin; J B Gouyon
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2001-01       Impact factor: 5.747

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.